fda warning letter bpc-157 compounding Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling fda warning letter bpc-157 unapproved

1 (2021): 112, 10.1186/s41983-021-00360-x

Healthcare professionals should maintain vigilance regarding these intersecting risk factors when managing patients on GLP-1 receptor agonists

Rare but Serious Complications Even though rare, serious problems can happen with Vitamin B12 shots

Some vaccine advisers to the federal government say theyre disappointed and angry that government scientists and the pharmaceutical company Moderna didnt present a set of infection data on the companys new Covid-19 booster during meetings last year when the advisers discussed whether the shot should be authorized and made available to the public

Building a MOTS-C Protocol Within a Longevity Program A MOTS-c protocol is most powerful not as a standalone intervention but as one layer of a structured longevity program that addresses mitochondrial health, metabolic flexibility, and body composition simultaneously